Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) went down by -3.73% from its latest closing price compared to the recent 1-year high of $63.55. The company’s stock price has collected -2.94% of loss in the last five trading sessions. Press Release reported on 01/05/22 that Maravai LifeSciences Announces Registration and Webcast Information for Upcoming R&D Day, to be Held on January 28, 2022
Is It Worth Investing in Maravai LifeSciences Holdings Inc. (NASDAQ :MRVI) Right Now?
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) scored a price-to-earnings ratio above its average ratio, recording 27.22 x from its present earnings ratio. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for Maravai LifeSciences Holdings Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $58.13, which is $25.05 above the current price. MRVI currently public float of 94.60M and currently shorts hold a 4.11% ratio of that float. Today, the average trading volume of MRVI was 1.48M shares.
MRVI’s Market Performance
MRVI stocks went down by -2.94% for the week, with a monthly drop of -17.70% and a quarterly performance of -13.43%, while its annual performance rate touched 22.03%. The volatility ratio for the week stands at 6.00% while the volatility levels for the past 30 days are set at 5.30% for Maravai LifeSciences Holdings Inc.. The simple moving average for the period of the last 20 days is -15.22% for MRVI stocks with a simple moving average of -21.91% for the last 200 days.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Credit Suisse repeating the rating for MRVI by listing it as a “Outperform.” The predicted price for MRVI in the upcoming period, according to Credit Suisse is $44 based on the research report published on August 05th of the previous year 2021.
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see MRVI reach a price target of $33. The rating they have provided for MRVI stocks is “Overweight” according to the report published on December 16th, 2020.
MRVI Trading at -16.44% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.96% of loss for the given period.
Volatility was left at 5.30%, however, over the last 30 days, the volatility rate increased by 6.00%, as shares sank -16.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.22% lower at present.
During the last 5 trading sessions, MRVI fell by -2.94%, which changed the moving average for the period of 200-days by -2.71% in comparison to the 20-day moving average, which settled at $38.69. In addition, Maravai LifeSciences Holdings Inc. saw -21.07% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- +35.52 for the present operating margin
- +69.29 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc. stands at +27.06. The total capital return value is set at 15.76, while invested capital returns managed to touch 12.79. Equity return is now at value 86.00, with 9.80 for asset returns.
Based on Maravai LifeSciences Holdings Inc. (MRVI), the company’s capital structure generated 667.47 points at debt to equity in total, while total debt to capital is 86.97. Total debt to assets is 46.49, with long-term debt to equity ratio resting at 660.69. Finally, the long-term debt to capital ratio is 86.09.
When we switch over and look at the enterprise to sales, we see a ratio of 5.49, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 8.11 and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.54.